TAHO Pharmaceuticals Ltd

TAHO Pharmaceuticals Ltd

TTPEX:6467
199.00
TWD
-20.00
(-9.13%)
-1.83EPS
5.76BMarket Cap
Dec 02Next Earn
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.46
0.41
0.67
0.69
0.24
0.03
- -
0.16
0.03
Basic EPS, GAAP
- -
-2.8
-2.52
-1.42
-2.09
-2.62
-3.12
-3.69
-4.16
-1.83
Free Cash Flow per Basic Share
- -
-2.95
-2.01
-1.64
-1.97
-2.65
-2.76
-3.65
-4.08
-1.7
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.77
7.64
9.44
8.07
5.97
3.32
4.89
10.08
8.09
6.58
Tangible Book Value per Share
2.18
6.29
8.63
7.56
5.56
2.98
4.89
10.08
8.08
6.57
Basic Weighted Avg Shares
52
31
50
52
52
52
39
45
51
52
Sales/Revenue/Turnover
- -
14
20
35
36
12
1
- -
8
1
Operating Margin (%)
- -
-615.34
-570.45
-363.1
-302.11
-864.87
-11,620.26
- -
-2,617.59
-7,251.93
Depreciation Expense
- -
17
19
18
17
16
8
7
9
5
Net Income, GAAP
- -
-87
-126
-74
-109
-137
-121
-167
-214
-96
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-605.43
-620.07
-211.88
-303.19
-1,105.89
-11,321.11
- -
-2,549.32
-7,099.33
Working Capital
103
305
421
335
238
119
174
466
368
287
LT Debt
- -
- -
- -
- -
- -
- -
17
11
6
3
Total Equity
197
400
494
422
313
173
207
516
424
345
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-29.05
-28.12
-16.23
-29.72
-56.44
-63.49
-46.32
-45.62
-24.94

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
6
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
6
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
52
52
52
Market Capitalization
5,838
6,834
5,765

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
394
351
304
Cash, Cash Equivalents & STI
390
347
300
Accounts Receivable, Net
- -
- -
1
Inventories
- -
- -
- -
Total Current Liabilities
26
20
17
Payables & Accruals
- -
- -
- -
ST Debt
6
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
16.11%
-17.92%
Free Cash Flow
- -
22.69%
26.74%
Net Income, GAAP
- -
25.46%
28.05%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
3
5
- -
- -
8
2026
- -
1
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
-3.69
2025
-0.48
-0.92
- -
- -
-4.16
2026
-0.82
-1.01
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Howard Lee
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Taipei Taiwan
Business
TAHO Pharmaceuticals Ltd is a Taiwan-based specialty pharmaceutical company engaged in the research, development, and commercialization of innovative drug delivery systems and 505(b)(2) reformulations of approved therapeutics. Founded in 2010 and headquartered in Taipei, Taiwan, the company focuses on improving patient compliance, bioavailability, and drug safety profiles across oncology supportive care, central nervous system disorders, and pain management. TAHO Pharmaceuticals operates through proprietary technology platforms, including its Oral Dissolving Film (ODF) platform, Transdermal Drug Delivery Systems (TDDS), and specialized mucosal absorption technologies. The company's core product portfolio and service offerings comprise TAHO-8801, an aprepitant oral dissolving film formulated for chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV); TAHO-4411, a transdermal patch formulation designed for antiemetic therapy; proprietary oral thin films and hydrogel/matrix patches targeting neurological conditions, cardiovascular diseases, and acute pain indications; pharmaceutical contract formulation development and optimization services; preclinical and clinical-stage development services; and intellectual property licensing and commercial rights partnerships for international markets. TAHO Pharmaceuticals serves healthcare institutions, commercial distributors, and multinational biopharmaceutical partners across Taiwan, the wider Asia-Pacific region, and North America. In recent developments, the company has advanced its clinical and regulatory milestones by pursuing 505(b)(2) New Drug Application pathways with the United States Food and Drug Administration (FDA) and regulatory filings with the Taiwan Food and Drug Administration (TFDA) for its lead oral thin film programs. In addition, the company has broadened its international presence through strategic out-licensing and co-development alliances with regional pharmaceutical partners, while expanding commercial-scale supply agreements with certified current Good Manufacturing Practice (cGMP) manufacturing facilities to support market launch readiness for its proprietary film and transdermal dosage forms.